Ocugen, Inc. (OCGN)

Market Cap	217.47M
Revenue (ttm)	4.70M
Net Income (ttm)	-51.14M
Shares Out	291.32M
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,324,013
Open	0.761
Previous Close	0.774
Day's Range	0.733 - 0.770
52-Week Range	0.458 - 2.105
Beta	3.82
Analysts	Strong Buy
Price Target	5.67 (+659.55%)
Earnings Date	Nov 8, 2024

About OCGN

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy un...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2013
• Employees: 65
• Stock Exchange: NASDAQ
• Ticker Symbol: OCGN
• Website: https://www.ocugen.com

Financial Performance

In 2023, Ocugen's revenue was $6.04 million, an increase of 142.60% compared to the previous year's $2.49 million. Losses were -$63.08 million, -27.33% less than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for OCGN stock is "Strong Buy." The 12-month stock price forecast is $5.67, which is an increase of 659.55% from the latest price.

Price Target

$5.67

(659.55% upside)

Analyst Consensus: Strong Buy